Tags

Type your tag names separated by a space and hit enter

Soy isoflavones prevent bone resorption and loss, a systematic review and meta-analysis of randomized controlled trials.
Crit Rev Food Sci Nutr. 2020; 60(14):2327-2341.CR

Abstract

BACKGROUND

Osteoporosis is a common bone disease characterized by reduced bone mass resulting from continuous bone resorption.

METHODS

PubMed, Scopus, and Embase were searched to find published trials on the effect of soy isoflavones on bone mineral density (BMD) and bone turnover markers (bone-specific alkaline phosphatase, osteocalcin, osteoprotegerin, pyridinoline, deoxypyridinoline, C-telopeptide, and N-telopeptide). Random-effects inverse-variance model was used to calculate the pooled effects.

RESULTS

A total of 5313 articles were found, screened, and assessed for eligibility, and finally 52 trials were included in the meta-analysis. Consumption of soy isoflavones caused significant improvement in BMD of lumbar spine (mean difference (MD) = 0.76%; 95% CI: 0.09, 1.42%; p = 0.03), hip (MD = 0.22%; 95% CI: 0.02, 0.42%; p = 0.04), and femoral neck (MD = 2.27%; 95% CI: 1.22, 3.31%; p < 0.001). Subgroup analysis showed that in all 3 sites, the improvement was significant in normal weight subjects and interventions longer than a year, although trial location and dosage were also factors influencing isoflavones' impact on BMD. Among markers of bone turnover, osteoprotegerin (MD = 5.79; 95% CI: 3.08, 8.51 pg/ml; p < 0.001), pyridinoline (MD = -5.13; 95% CI: -7.76, -2.50 nmol/mmol; p < 0.001), and C-telopeptides (MD = -0.08; 95% CI: -0.16, -0.00 ng/ml; p = 0.04) were favorably affected by isoflavones while osteocalcin and bone alkaline phosphatase did not change. Subgroup analysis of bone markers showed that in overweight/obese individuals and dosages <90 mg/day, isoflavones are more effective.

CONCLUSIONS

Soy isoflavones prevent osteoporosis-related bone loss in any weight status or treatment duration. They increase BMD in normal weight subjects and diminish bone resorption in overweight/obese individuals. Although bone resorption may be decelerated over short-term isoflavone consumption, periods longer than a year are probably needed to affect BMD. Isoflavones also appear benefits on bone in any dose or subjects' ethnicity.

Authors+Show Affiliations

School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

31290343

Citation

Akhlaghi, Masoumeh, et al. "Soy Isoflavones Prevent Bone Resorption and Loss, a Systematic Review and Meta-analysis of Randomized Controlled Trials." Critical Reviews in Food Science and Nutrition, vol. 60, no. 14, 2020, pp. 2327-2341.
Akhlaghi M, Ghasemi Nasab M, Riasatian M, et al. Soy isoflavones prevent bone resorption and loss, a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2020;60(14):2327-2341.
Akhlaghi, M., Ghasemi Nasab, M., Riasatian, M., & Sadeghi, F. (2020). Soy isoflavones prevent bone resorption and loss, a systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Food Science and Nutrition, 60(14), 2327-2341. https://doi.org/10.1080/10408398.2019.1635078
Akhlaghi M, et al. Soy Isoflavones Prevent Bone Resorption and Loss, a Systematic Review and Meta-analysis of Randomized Controlled Trials. Crit Rev Food Sci Nutr. 2020;60(14):2327-2341. PubMed PMID: 31290343.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soy isoflavones prevent bone resorption and loss, a systematic review and meta-analysis of randomized controlled trials. AU - Akhlaghi,Masoumeh, AU - Ghasemi Nasab,Maryam, AU - Riasatian,Maryam, AU - Sadeghi,Fatemeh, Y1 - 2019/07/10/ PY - 2019/7/11/pubmed PY - 2020/9/17/medline PY - 2019/7/11/entrez KW - BMD KW - Isoflavones KW - bone KW - bone mineral density KW - bone resorption KW - bone turnover markers SP - 2327 EP - 2341 JF - Critical reviews in food science and nutrition JO - Crit Rev Food Sci Nutr VL - 60 IS - 14 N2 - BACKGROUND: Osteoporosis is a common bone disease characterized by reduced bone mass resulting from continuous bone resorption. METHODS: PubMed, Scopus, and Embase were searched to find published trials on the effect of soy isoflavones on bone mineral density (BMD) and bone turnover markers (bone-specific alkaline phosphatase, osteocalcin, osteoprotegerin, pyridinoline, deoxypyridinoline, C-telopeptide, and N-telopeptide). Random-effects inverse-variance model was used to calculate the pooled effects. RESULTS: A total of 5313 articles were found, screened, and assessed for eligibility, and finally 52 trials were included in the meta-analysis. Consumption of soy isoflavones caused significant improvement in BMD of lumbar spine (mean difference (MD) = 0.76%; 95% CI: 0.09, 1.42%; p = 0.03), hip (MD = 0.22%; 95% CI: 0.02, 0.42%; p = 0.04), and femoral neck (MD = 2.27%; 95% CI: 1.22, 3.31%; p < 0.001). Subgroup analysis showed that in all 3 sites, the improvement was significant in normal weight subjects and interventions longer than a year, although trial location and dosage were also factors influencing isoflavones' impact on BMD. Among markers of bone turnover, osteoprotegerin (MD = 5.79; 95% CI: 3.08, 8.51 pg/ml; p < 0.001), pyridinoline (MD = -5.13; 95% CI: -7.76, -2.50 nmol/mmol; p < 0.001), and C-telopeptides (MD = -0.08; 95% CI: -0.16, -0.00 ng/ml; p = 0.04) were favorably affected by isoflavones while osteocalcin and bone alkaline phosphatase did not change. Subgroup analysis of bone markers showed that in overweight/obese individuals and dosages <90 mg/day, isoflavones are more effective. CONCLUSIONS: Soy isoflavones prevent osteoporosis-related bone loss in any weight status or treatment duration. They increase BMD in normal weight subjects and diminish bone resorption in overweight/obese individuals. Although bone resorption may be decelerated over short-term isoflavone consumption, periods longer than a year are probably needed to affect BMD. Isoflavones also appear benefits on bone in any dose or subjects' ethnicity. SN - 1549-7852 UR - https://www.unboundmedicine.com/medline/citation/31290343/Soy_isoflavones_prevent_bone_resorption_and_loss_a_systematic_review_and_meta_analysis_of_randomized_controlled_trials_ L2 - https://www.tandfonline.com/doi/full/10.1080/10408398.2019.1635078 DB - PRIME DP - Unbound Medicine ER -